Zacks Investment Research
23 Jul 2026, 22:51 UTC · 2h ago
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
23 Jul 2026, 22:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Amgen is currently assigned a Zacks Rank of #4 (Sell). — A 'Sell' rating from a quantitative research provider typically triggers selling pressure or cautious sentiment among retail and institutional investors.
-0.50Amgen's anticipated EPS for the upcoming August 4, 2026 earnings report is $5.6, a projected 6.98% decrease year-over-year. — Expected earnings contraction usually weighs on a stock's price leading up to the reporting date.
-0.40The Zacks Consensus EPS estimate for Amgen has shifted 0.34% downward over the past month. — Downward revisions in analyst estimates are generally viewed as a bearish signal for short-term price action.
-0.20Continue reading
6 related stories
Top 3 movers · tap to explore
Amgen's projected full-year revenue is $37.73 billion, representing a 2.67% increase from the prior year. — Slight revenue growth provides a minor positive offset to the projected earnings decline.
Which stocks this story touches
Despite a daily price gain, the company has a Zacks Rank of #4 (Sell) and an expected EPS decline of 6.98% for the upcoming quarter.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
No cluster impact found for this article yet.
Zacks Investment Research
2h ago
